Sofinno­va Ven­tures ups the ante - again - as it clos­es in on $650M biotech fund

Sofinno­va Ven­tures is close to cap­ping off a new $650 mil­lion biotech fund. Ear­li­er in the week the Sil­i­con Val­ley-based VC group post­ed an SEC fil­ing not­ing that it has round­ed up $595.5 mil­lion for Sofinno­va Ven­ture Part­ners X.

This 10th fund is al­ready well ahead of the $500 mil­lion Sofinno­va raised for its 9th fund back in the sum­mer of 2014. And it will be sub­stan­tial­ly big­ger than fund 8, which raised $440 mil­lion. James Healy is the gen­er­al part­ner.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.